ALLMedicine™ Acute Lymphoblastic Leukemia Center
Research & Reviews 6,362 results
https://doi.org/10.1002/pbc.29184
Pediatric Blood & Cancer; Küpfer L, Meng B et. al.
Jul 29th, 2021 - We report a retrospective analysis of 110 unselected pediatric patients with acute lymphoblastic leukemia (ALL) treated during 2015-2017 in a charity-funded public institution in Cambodia with a reduced intensity ALL-Moscow Berlin (MB)-91 protocol...
https://doi.org/10.1080/17474086.2021.1960817
Expert Review of Hematology; Baek DW, Lee JM et. al.
Jul 28th, 2021 - The long-term survival of relapsed/refractory (R/R) adult T-cell acute lymphoblastic leukemia (T-ALL) is quite poor, and early T-cell precursor (ETP) ALL has recently been described as a high-risk T-ALL subgroup. However, the optimal therapeutic a...
https://doi.org/10.1038/s41591-021-01436-0 10.1172/JCI85309 10.1016/S1470-2045(18)30864-7 10.1056/NEJMoa1707447 10.1056/NEJMoa1804980 10.1182/blood-2018-11-883710 10.1056/NEJMoa1709866 10.1056/NEJMoa1709919 10.1200/JCO.19.02104 10.1182/blood-2019-127508 10.1016/S0140-6736(14)61403-3 10.1056/NEJMoa1910607 10.1158/2159-8290.CD-18-0442 10.1128/MCB.00383-18 10.1038/s41375-019-0580-z 10.1038/s41591-018-0146-z 10.1158/2159-8290.CD-15-1020 10.1158/1078-0432.CCR-18-0432 10.4049/jimmunol.1402346 10.1038/mt.2016.82 10.1016/j.ymthe.2017.06.008 10.1158/2159-8290.CD-19-0945 10.1038/nm.4441 10.1172/JCI126397 10.1182/blood-2018-99-120206 10.1182/blood-2019-126218 10.1002/pbc.25410 10.1182/blood-2012-06-438002 10.1016/S0065-2776(05)88001-0 10.3109/10428194.2011.559668 10.1080/08820130500496878 10.1200/JCO.19.03279 10.1016/j.omto.2018.10.006 10.1126/science.aba1786 10.1002/ajh.24594 10.1182/blood.2020009432 10.1182/blood-2015-08-665547 10.1038/ncomms12320 10.1056/NEJMoa1708566 10.3324/haematol.2017.183459 10.1182/blood-2016-04-711903 10.1172/JCI83416 10.1093/neuonc/nox182 10.1038/s41467-020-16160-5 10.1182/blood.2019002779 10.1182/bloodadvances.2019000703 10.1038/s41591-020-1081-3 10.1182/blood-2020-140907 10.1200/JCO.2020.38.15_suppl.3035 10.1038/s41375-020-0792-2 10.1186/s13045-020-00856-8 10.1182/blood-2019-123424 10.1038/s41586-019-1805-z 10.1097/01.cji.0000161397.96582.59 10.1158/1078-0432.CCR-13-0330 10.4161/onci.23621 10.1053/j.gastro.2020.02.011 10.1182/blood-2019-131024 10.1038/mtna.2013.32 10.1158/2326-6066.CIR-15-0231 10.1007/s00262-018-2155-7 10.1182/blood-2014-01-552174 10.1182/bloodadvances.2020003092 10.1200/JCO.2013.54.8800 10.1182/blood-2014-05-552729 10.1016/j.bbmt.2018.12.758 10.1093/nar/gkm861 10.1371/journal.pone.0057838 10.1186/s12885-020-07077-9
Nature Medicine; Spiegel JY, Patel S et. al.
Jul 28th, 2021 - Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 ...
https://doi.org/10.1001/jama.2021.8154
JAMA Locatelli F, Zugmaier G et. al.
Jul 28th, 2021 - Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia-Reply.|2021|Locatelli F,Zugmaier G,von Stackelberg A,|
https://doi.org/10.1001/jama.2021.8151
JAMA Shibusawa M, Kidoguchi K et. al.
Jul 28th, 2021 - Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia.|2021|Shibusawa M,Kidoguchi K,Tanimoto T,|
Guidelines 3 results
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.
Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.
Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.
Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...
Drugs 109 results see all →
Clinicaltrials.gov 386 results
https://clinicaltrials.gov/ct2/show/NCT03677596
May 7th, 2020 - This study will explore 2 different doses of inotuzumab ozogamicin including the dose that is approved and a lower dose. The main purpose of this study is to evaluate whether a dose of inotuzumab ozogamicin, lower than the approved dose, could be ...
https://clinicaltrials.gov/ct2/show/NCT02535364
May 4th, 2020 - This is a single-arm, multicenter Phase 2 study to determine the efficacy and safety of JCAR015 in adult patients with relapsed or refractory B-ALL. The study will have the following sequential phases: Part A (screening, leukapheresis, cell produc...
https://clinicaltrials.gov/ct2/show/NCT03670966
May 1st, 2020 - OUTLINE: This is a dose-escalation study of astatine At 211 anti-CD45 monoclonal antibody BC8-B10. PREPARATIVE REGIMEN: Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 infusion on day -8, fludarabine intravenously (IV) over ...
https://clinicaltrials.gov/ct2/show/NCT03286114
Apr 28th, 2020 - This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving allogeneic hematopo...
https://clinicaltrials.gov/ct2/show/NCT03204916
Apr 27th, 2020 - PRIMARY OBJECTIVES: I. To evaluate the proportion of adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients with a documented treatment plan consistent with NCCN guidelines for AYAs with ALL. II. To evaluate the proportion of...
News 689 results
https://www.medscape.com/viewarticle/954149
Jul 2nd, 2021 - The US Food and Drug Administration (FDA) has approved a new version of asparaginase for use in children and adults who have developed hypersensitivity to asparaginase derived from Escherichia coli. The new product is Jazz Pharmaceutical's Rylaze ...
https://www.medscape.com/viewarticle/952355
Jun 3rd, 2021 - Data from a small retrospective study suggest that venetoclax-based regimens may have activity against relapsed or refractory T-lineage acute lymphoblastic leukemia (T-ALL) in children and young adults. Among seven patients with T-ALL treated with...
https://www.medscape.com/viewarticle/951639
May 21st, 2021 - Even in the age of intensive therapy and extensive risk stratification, there are small but significant differences in outcomes between boys and girls with B-lineage acute lymphoblastic leukemia (B-ALL). This finding comes from a review of 10 year...
https://www.medscape.com/viewarticle/948896
Apr 7th, 2021 - Children and adolescents with leukemia who were placed on a restrictive diet and exercise regimen concurrent with starting chemotherapy showed responses to treatment that were better than those historically seen in such patients. This apparently i...
https://www.medscape.com/viewarticle/948153
Mar 25th, 2021 - The use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival in minimal residual disease (MRD)-negative remission patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) after the start...
